Hematopoietic Stem Cell Mobilization

PROCEDURE2 trials

Sponsors

National Cancer Institute (NCI), Institute of Hematology and Immunology “Dr. Jose Manuel Ballester Santovenia”

Conditions

DS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell MyelomaLung lesions COVID-19Refractory Plasma Cell Myeloma

Phase 2

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

WithdrawnNCT01251172

National Cancer Institute (NCI)DS Stage III Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage I Plasma Cell Myeloma +1

Start: 2010-12-31Updated: 2017-09-28

Unknown Phase

Stem cells in patients with lung lesions (COVID-19)

RecruitingRPCEC00000322

Institute of Hematology and Immunology “Dr. Jose Manuel Ballester Santovenia”Lung lesions COVID-19

Start: 2020-05-05Target: 20Updated: 2026-03-30